Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...
Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.
Pharmaceutical Technology on MSN
Massive sales for weight loss drugs spur Eli Lilly’s Q3
"Massive sales for weight loss drugs spur Eli Lilly’s Q3" was originally created and published by Pharmaceutical Technology, ...
U.S. pharmaceutical company Eli Lilly (LLY) says that the weight-loss pill it is developing should be a candidate for ...
Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...
TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...
Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.
Changes to vaccine recommendations under Health Secretary Robert F. Kennedy Jr. are confusing professionals in the pharmaceutical and insurance industries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback